Print page content Print
Increase text size Decrease text size
Text Size

side effects

CYTOPOINT® side effects

Adverse health events were comparable to placebo in client-owned dogs1*

Adverse Events Reported In >2% of Dogs in a Field Safety Study1†
Abnormal Health Event Preferred Term Placebo (N  = 83 dogs) CYTOPOINT (N = 162 dogs)
Otitis Externa 12.0% (10) 13.0% (21)
Dermatitis 13.3% (11) 9.9% (16)
Bacterial Skin Infection 12.0% (10) 9.3% (15)
Erythema 4.8% (4) 8.0% (13)
Vomiting 10.8% (9) 7.4% (12)
Anorexia 4.8% (4) 6.2% (10)
Lethargy 6.0% (5) 5.6% (9)
Pruritus 19.3% (16) 4.9% (8)
Diarrhea 4.8% (4) 3.7% (6)
Alopecia 7.2% (6) 2.5% (4)
  • Cases of vomiting, diarrhea and lethargy resolved without treatment1

  • Other than pruritus and alopecia, which were substantially more common in dogs receiving placebo.1
  • Occurrence calculated on a per-case basis—no matter how many observations of the same abnormal health event a dog had, it contributed one observation to the occurrence calculation.1

Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.



Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2022 Zoetis Services LLC. All rights reserved.